您当前的位置:
技术服务
发布日期:2024/6/28 16:20:00

Title:Effect of Parecoxib on Postoperative Opioid Requirement and Pain Control

标题:帕瑞昔布对术后阿片类药物需求和疼痛控制的影响

Authors: Jun Tang, et al.

作者:Jun Tang 等

Published in: Anesthesiology, 2002

发表期刊:《麻醉学》,2002年

Objective:

The study aimed to evaluate the effectiveness of parecoxib, an intravenous COX-2 inhibitor, in reducing postoperative opioid requirements and enhancing the quality of pain control in patients undergoing surgery.

研究目的:

评估帕瑞昔布(静脉环氧合酶-2抑制剂)在减少术后阿片类药物需求量及提高疼痛控制质量方面的效果。

Methodology:

Study Design: Double-blind, placebo-controlled trial
Participants: Patients scheduled for various types of surgeries
Interventions: Patients were randomized to receive either parecoxib or a placebo.
Measurements: Postoperative opioid consumption, pain intensity scores, and adverse effects were recorded and analyzed.

方法:

研究设计:双盲、安慰剂对照试验
参与者:计划进行各种类型手术的患者
干预措施:患者被随机分配接受帕瑞昔布或安慰剂。
测量:记录并分析术后阿片类药物消耗量、疼痛强度评分及不良反应。

Key Findings:

Reduction in Opioid Use: Patients receiving parecoxib required significantly less postoperative opioids compared to the placebo group.
Improved Pain Control: The quality of pain control was better in the parecoxib group, as evidenced by lower pain intensity scores.
Safety and Tolerability: Parecoxib was well tolerated with a safety profile similar to the placebo.

主要发现:

减少阿片类药物使用:接受帕瑞昔布的患者术后所需阿片类药物显著少于安慰剂组。
疼痛控制改善:帕瑞昔布组的疼痛控制质量更好,疼痛强度评分较低。
安全性和耐受性:帕瑞昔布耐受性良好,其安全性与安慰剂相似。

Conclusion:

Parecoxib is an effective analgesic that reduces the need for opioids and improves pain management postoperatively without increasing adverse effects.

结论:

帕瑞昔布是一种有效的镇痛药,可减少术后阿片类药物的使用并改善疼痛管理,同时不增加不良反应。

相关化合物及其CAS号

1. **Parecoxib (帕瑞昔布)**
   - **CAS Number:** 198470-85-8
2. **Celecoxib (塞来昔布)**
   - **CAS Number:** 169590-42-5
3. **Rofecoxib (罗非昔布)**
   - **CAS Number:** 162011-90-7
4. **Ketorolac (酮咯酸)**
   - **CAS Number:** 74103-07-4

相关产品

罗非昔布 162011-90-7
|250mg
Celecoxib. 169590-42-5
|10mM (in 1mL DMSO)
Parecoxib Sodium. 198470-85-8
|50mg
Ketorolac tromethamine salt 74103-07-4
|1g
上一篇:环氧化酶-2 (COX-2) 选择性抑制剂塞来昔布和帕瑞昔布:系统 下一篇:维生素D受体激动剂帕里卡托尔预防压力超载小鼠模型中的纤维化和舒张功能障碍